<DOC>
	<DOCNO>NCT00019344</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase I trial study effectiveness flavopiridol treat patient refractory cancer .</brief_summary>
	<brief_title>Flavopiridol Treating Patients With Refractory Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine dose-limiting toxicity maximum tolerate dose flavopiridol patient refractory solid tumor lymphoma . 2 . Determine pharmacokinetics drug patient . OUTLINE : This dose-escalation study . Patients receive flavopiridol IV 1 hour day 1 . Treatment continue every 3 week absence disease progression . A cohort 3-6 patient receive treatment dose level flavopiridol . If dose-limiting toxicity ( DLT ) occur 1 6 patient , subsequent cohort 6 patient receive escalating dos drug schedule . Intrapatient dose escalation next level permit absence DLT . PROJECTED ACCRUAL : Approximately 36 patient accrue study within 27 month .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Intestinal Neoplasms</mesh_term>
	<mesh_term>Alvocidib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven refractory solid tumor lymphoma require systemic therapy No standard therapeutic option exist Prostate cancer patient : Tumor progression blockade testicular adrenal androgen require PSA elevation 2 consecutive blood sample , 2 week apart Serum testosterone concentration castrate range Leuprolide gonadotropinreleasing hormone ( GnRH ) analog maintain prior orchiectomy No CNS neoplasms PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Platelet count least 75,000/mm3 Absolute granulocyte count least 1,000/mm3 No active coagulopathy require therapeutic anticoagulation Hepatic : SGOT SGPT great 2.5 time normal Bilirubin great 1.5 time normal ( 3 time normal Gilbert 's disease present ) Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance least 60 mL/min Cardiovascular : No history unstable newly diagnose angina pectoris No myocardial infarction within past 6 month No New York Heart Association class IIIV heart disease Other : No serious concurrent medical illness HIV negative Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month study PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) recover No prior flavopiridol Endocrine therapy : See Disease Characteristics A least 4 week since prior flutamide antiandrogen therapy without disease improvement At least 4 week since prior hormonal therapy breast carcinoma must show evidence disease progression No concurrent corticosteroid except physiological replacement Radiotherapy : At least 4 week since prior radiotherapy recover At least 6 week since prior boneseeking radioisotope therapy Surgery : Not specify Other : At least 3 month since prior suramin treatment At least 2 month since prior UCN01 No concurrent anticoagulation therapy No concurrent antineoplastic therapy except GnRH prostate cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2002</verification_date>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>small intestine lymphoma</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>intraocular lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>